@EricTopol @VirusesImmunity @DanaFarber @NEJM It’s not to say that gp100 is a bad target. In fact, it has recently been approved in the form of tebentafusp, a CD3-TCR bispecific targeting GP100 in uveal melanoma for individuals with HLA A2: https://t.co/l…
Interesting illustration of what you may find, developing successful immunotherapies for solid tumors: improved overall survival in the absence of Overall Response Rates (a surrogate marker that was not developed for the evaluation of immunotherapies) h…
RT @DrVijayPatil11: Tebentafusp in uveal melanoma https://t.co/xkdc7Mv2Bd
Tebentafusp in uveal melanoma https://t.co/xkdc7Mv2Bd